Abstract 1765P
Background
For unresectable or metastatic gastrointestinal stromal tumors (GISTs), sunitinib is the standard second-line treatment. However, other tyrosine kinase inhibitors also demonstrate clinical activity. This prospective, multicenter, observational real-world study aims to explore the second-line targeted therapy patterns and clinical outcomes in GIST patients who progressed on or were intolerant to first-line treatment.
Methods
Patients with advanced GISTs who had progressed or intolerant to first-line therapy were enrolled in the study. The second-line regimen for them was determined based on the judgement by investigators. Enrolment of 100 patients is planned. The primary endpoint is progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoint includes safety.
Results
It is an early result from analysis of 39 patients (ripretinib, n=16; sunitinib, n=20; regorafenib, n=3). Among the patients treated with ripretinib, 81% (13/16) patients had a primary mutation in KIT exon 11. For patients with sunitinib, 55% (11/20) had a primary mutation in KIT exon 9. All patients (100%) with regorafenib carried a secondary mutation in KIT exon 17. Objective response rates were 31% (5/16), 0 and 0 in ripretinib, sunitinib and regorafenib respectively. Median PFS (mPFS) for ripretinib, sunitinib and regorafenib were 11.2, 11.1 and 2.8 months, respectively (P = 0.589). For those with primary KIT exon 11 mutation, mPFS were 10.4, 1.4 and 3.1 months for ripretinib, sunitinib and regorafenib, respectively (P = 0.0045). All grades TEAEs were mostly lower with ripretinib versus sunitinib. And ripretinib was associated with fewer grade 3/4 TEAEs against sunitinib (12.5% vs 40%, p=0.0672).
Conclusions
As a second-line treatment for advanced GIST patients, mPFS was significantly prolonged in the ripretinib group compared to those treated with sunitinib or regorafenib for patients with primary KIT exon 11 mutations. At the same time, ripretinib was associated with lower occurrences of TEAEs with less severity.
Clinical trial identification
NCT05440357 release date: 6/27/2022.
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1362P - Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)
Presenter: Omar Khan
Session: Poster session 06
1363P - An AI-derived tool to pre-screen lung cancer candidates for clinical trials
Presenter: Mihaela Aldea
Session: Poster session 06
1364P - Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE)
Presenter: Åsa Öjlert
Session: Poster session 06
1365P - Does cancer care differ for older adults with lung cancer living with and without Alzheimer disease and related dementias (ADRD)?
Presenter: Lorinda Coombs
Session: Poster session 06
1366P - Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort
Presenter: Julien Mazieres
Session: Poster session 06
1367P - Sex disparities in patient and tumour characteristics, and overall survival in advanced non-small cell lung cancer (NSCLC) within the precision oncology era: A Danish nationwide observational study
Presenter: Matilde Frost
Session: Poster session 06
1368P - Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
Presenter: Fabien Moinard-Butot
Session: Poster session 06
1369P - Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial
Presenter: Shen Cun Fang
Session: Poster session 06
1370P - Survival of de novo metastatic non-small cell lung cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 06